Abstract:The human immunodeficiency virus (HIV) nucleocapsid protein (NCp7) plays significant roles in the virus life cycle and has been targeted by compounds that could lead to its denaturation or block its interaction with viral RNA. Herein, we describe the interactions of platinum(II) and gold(III) complexes with NCp7 and how the reactivity/affinity of potential inhibitors can be modulated by judicious choice of ligands. The interactions of [MCl(N3)]n+ (M = Pt2+ (n = 1) and Au3+ (n = 2); N3 = tridentate chelate ligands: bis(2-pyridylmethyl)methylamine (Mebpma, L1) and bis(2-pyridylmethyl)amine (bpma, L2) with the C-terminal zinc finger of NCp7 (ZF2) were investigated by electrospray ionization-mass spectroscopy (ESI-MS). Mass spectra from the incubation of [MCl(Mebpma)]n+ complexes (PtL1 and AuL1) with ZF2 indicated that they were more reactive than the previously studied diethylenetriamine-containing analogues [MCl(dien)]n+. The initial product of reaction of PtL1 with ZF2 results in loss of all ligands and release of zinc to give the platinated apopeptide {PtF} (F = apopeptide). This is in contrast to the incubation with [PtCl(dien)]+, in which {Pt(dien)}-peptide adducts are observed. Incubation of the Au3+ complex AuL1 with ZF2 gave AuxFn+ species (x = 1, 2, 4, F = apopeptide) again with loss of all ligands. Furthermore, the formally substitution-inert analogues [Pt(N3)L]2+ (L = 4-methylpyridine (4-pic), 4-dimethylaminopyridine (dmap), and 9-ethylguanine (9-EtGua)) were prepared to examine stacking interactions with N-acetyltryptophan (N-AcTrp), the Trp-containing ZF2, and the "full" two-finger NCp7 itself using fluorescence quenching titration. Use of bpma and Mebpma gave slightly higher affinity than analogous [Pt(dien)L)]2+ complexes. The dmap-containing complexes (PtL1a and PtL2a) had the greatest association constants (Ka) for N-AcTrp and ZF2 peptide. The complex PtL1a had the highest Ka when compared with other known Pt2+ analogues: [Pt(dien)(9-EtGua)]2+ < [Pt(bpma)(9-EtGua)]2+ < [Pt(dien)(dmap)]2+< PtL2a < PtL1a. A Ka value of ca. 40.6 ± 1.0 × 103 M-1 was obtained for the full NCp7 peptide with PtL1a. In addition, the mass spectrum of the interaction between ZF2 and PtL1a confirms formation of a 1:1 PtL1a/ZF2 adduct. The reactivity of selected complexes with sulfur-containing amino acid N-acetylcysteine (N-AcCys) was also investigated by 195Pt and 1H NMR spectroscopy and ESI-MS. The precursor compounds [PtCl(N3)]+ PtL1 and PtL2 reacted readily, whereas their [Pt(N3)L]2+ analogues PtL1a and PtL2a were inert to substitution.

Selective Targeting of the Zinc Finger Domain of HIV Nucleocapsid Protein NCp7 with Ruthenium Complexes.

Covalent Versus Noncovalent Binding of Ruthenium Eta(6)-P-cymene Complexes to Zinc-Finger Protein NCp7

Interaction of the HIV NCp7 Protein with Platinum(II) and Gold(III) Complexes Containing Tridentate Ligands

TAR RNA selective targeting ruthenium(II) complexes as HIV-1 reverse transcriptase inhibitors: On exploring structure-activity relationships of multiple positions

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Selective Cleavage of DNA at Guanosine Bases Which Locate in DNA Non-Duplex Portions Within Duplexes by Ruthenium(ii) Complexes

Selective Nuclei Accumulation of Ruthenium(ii) Complex Enantiomers That Target G-quadruplex DNA.

The ruthenium complex assists in nuclear targeting and selective killing of tumor cells

Increasing the cytotoxicity of Ru(II) polypyridyl complexes by tuning the electron donating ability of 1,10-phenanthroline ligands

Ruthenium(II) complexes as mitochondrial inhibitors of topoisomerase induced A549 cell apoptosis

Terpyridyl ruthenium complexes as visible spectral probe for poly(A) RNA and bifunctional TAR RNA binders and HIV-1 reverse transcriptase inhibitors

Synthesis, Cytotoxicity, and Biomacromolecule Binding: Three Isomers of Nitrosylruthenium Complexes with Bidentate Bioactive Molecules As Co-Ligands

Α‐synuclein As a Target for Metallo‐Anti‐Neurodegenerative Agents

From Intercalation to External Binding: Ru(II) Complexes with a Spiro Ligand for TAR RNA Selective Binding and HIV-1 Reverse Transcriptase Inhibition

DNA Interaction, DNA Photocleavage, Photocytotoxicity In Vitro, and Molecular Docking of Naphthyl-Appended Ruthenium Complexes

New ruthenium polypyridyl complexes functionalized with fluorine atom or furan: Synthesis, DNA-binding, cytotoxicity and antitumor mechanism studies

Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands

Mononuclear η6-arene ruthenium(II) complexes with pyrazolyl-pyridazine ligands: synthesis, CT-DNA binding, reactivity towards glutathione, and cytotoxicity

Experimental determination and calculations of redox potential descriptors of compounds directed against retroviral zinc fingers: Implications for rational drug design

Ruthenium(II) Polypyridyl Complexes: Cellular Uptake, Cell Image and Apoptosis of HeLa Cancer Cells Induced by Double Targets

Nano-Crystallites of Ruthenium(III) Violurate Complex: Synthesis, Characterization, PXRD and DFT Structural Analysis. DNA/ HSA -Binding, Antiviral Activity Against COVID-19 and Molecular Docking Study